Author
Listed:
- Yue Fu
(Genomics Institute of the Novartis Research Foundation)
- David Estoppey
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Silvio Roggo
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Dominik Pistorius
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Florian Fuchs
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Christian Studer
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Ashraf S. Ibrahim
(The Lundquist Institute for Biomedical Innovations at Harbor-University of California at Los Angeles (UCLA) Medical Center
David Geffen School of Medicine at UCLA)
- Thomas Aust
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Frederic Grandjean
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Manuel Mihalic
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Klaus Memmert
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Vivian Prindle
(Genomics Institute of the Novartis Research Foundation)
- Etienne Richard
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Ralph Riedl
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Sven Schuierer
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Eric Weber
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Jürg Hunziker
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Frank Petersen
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
- Jianshi Tao
(Genomics Institute of the Novartis Research Foundation)
- Dominic Hoepfner
(Novartis Institutes for BioMedical Research, Novartis Pharma AG)
Abstract
Biosynthesis of glycosylphosphatidylinositol (GPI) is required for anchoring proteins to the plasma membrane, and is essential for the integrity of the fungal cell wall. Here, we use a reporter gene-based screen in Saccharomyces cerevisiae for the discovery of antifungal inhibitors of GPI-anchoring of proteins, and identify the oligocyclopropyl-containing natural product jawsamycin (FR-900848) as a potent hit. The compound targets the catalytic subunit Spt14 (also referred to as Gpi3) of the fungal UDP-glycosyltransferase, the first step in GPI biosynthesis, with good selectivity over the human functional homolog PIG-A. Jawsamycin displays antifungal activity in vitro against several pathogenic fungi including Mucorales, and in vivo in a mouse model of invasive pulmonary mucormycosis due to Rhyzopus delemar infection. Our results provide a starting point for the development of Spt14 inhibitors for treatment of invasive fungal infections.
Suggested Citation
Yue Fu & David Estoppey & Silvio Roggo & Dominik Pistorius & Florian Fuchs & Christian Studer & Ashraf S. Ibrahim & Thomas Aust & Frederic Grandjean & Manuel Mihalic & Klaus Memmert & Vivian Prindle &, 2020.
"Jawsamycin exhibits in vivo antifungal properties by inhibiting Spt14/Gpi3-mediated biosynthesis of glycosylphosphatidylinositol,"
Nature Communications, Nature, vol. 11(1), pages 1-12, December.
Handle:
RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17221-5
DOI: 10.1038/s41467-020-17221-5
Download full text from publisher
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Yidan Xu & Tingting Li & Zixuan Zhou & Jingjing Hong & Yulin Chao & Zhini Zhu & Ying Zhang & Qianhui Qu & Dianfan Li, 2023.
"Structures of liganded glycosylphosphatidylinositol transamidase illuminate GPI-AP biogenesis,"
Nature Communications, Nature, vol. 14(1), pages 1-17, December.
- Jingjing Hong & Tingting Li & Yulin Chao & Yidan Xu & Zhini Zhu & Zixuan Zhou & Weijie Gu & Qianhui Qu & Dianfan Li, 2024.
"Molecular basis of the inositol deacylase PGAP1 involved in quality control of GPI-AP biogenesis,"
Nature Communications, Nature, vol. 15(1), pages 1-17, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:11:y:2020:i:1:d:10.1038_s41467-020-17221-5. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.